Eculizumab for the treatment of an atypical hemolytic uremic syndrome with mutations in complement factor I and C3

array:24 ["pii" => "S0211699515001538" "issn" => "02116995" "doi" => "10.1016/j.nefro.2015.07.007" "estado" => "S300" "fechaPublicacion" => "2016-01-01" "aid" => "101" "copyright" => "Sociedad Española de Nefrología" "copyrightAnyo" => "2015" "documento" => "simple-article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "cor" "cita" => "Nefrologia. 2016;36:72-5" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 5671 "formatos" => array:3 [ "EPUB" => 305 "HTML" => 4601 "PDF" => 765 ] ] "itemSiguiente" => array:19 [ "pii" => "S0211699515001381" "issn" => "02116995" "doi" => "10.1016/j.nefro.2015.08.003" "estado" => "S300" "fechaPublicacion" => "2016-01-01" "aid" => "86" "copyright" => "Sociedad Española de Nefrología" "documento" => "simple-article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "cor" "cita" => "Nefrologia. 2016;36:75-6" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 5482 "formatos" => array:3 [ "EPUB" => 387 "HTML" => 4255 "PDF" => 840 ] ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "Letter to the Editor" "titulo" => "Methylmalonic acidemia with emergency hypertension" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "75" "paginaFinal" => "76" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Acidemia metilmalónica con hipertensión de emergencia" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Bahareh Yaghmaei, Parastoo Rostami, Farnaz Najmi Varzaneh, Behdad Gharib, Behnaz Bazargani, Nima Rezaei" "autores" => array:6 [ 0 => array:2 [ "nombre" => "Bahareh" "apellidos" => "Yaghmaei" ] 1 => array:2 [ "nombre" => "Parastoo" "apellidos" => "Rostami" ] 2 => array:2 [ "nombre" => "Farnaz Najmi" "apellidos" => "Varzaneh" ] 3 => array:2 [ "nombre" => "Behdad" "apellidos" => "Gharib" ] 4 => array:2 [ "nombre" => "Behnaz" "apellidos" => "Bazargani" ] 5 => array:2 [ "nombre" => "Nima" "apellidos" => "Rezaei" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0211699515001381?idApp=UINPBA000064" "url" => "/02116995/0000003600000001/v1_201602110042/S0211699515001381/v1_201602110042/en/main.assets" ] "itemAnterior" => array:20 [ "pii" => "S0211699515001411" "issn" => "02116995" "doi" => "10.1016/j.nefro.2015.09.003" "estado" => "S300" "fechaPublicacion" => "2016-01-01" "aid" => "89" "copyright" => "Sociedad Española de Nefrología" "documento" => "simple-article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "crp" "cita" => "Nefrologia. 2016;36:69-71" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 10984 "formatos" => array:3 [ "EPUB" => 346 "HTML" => 9417 "PDF" => 1221 ] ] "es" => array:11 [ "idiomaDefecto" => true "cabecera" => "Carta al Director: Comentarios breves sobre casos clínicos" "titulo" => "Nefritis intersticial aguda por ibuprofeno en población pediátrica" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "69" "paginaFinal" => "71" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Ibuprofen-induced acute interstitial nephritis in the paediatric population" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1974 "Ancho" => 1658 "Tamanyo" => 175863 ] ] "descripcion" => array:1 [ "es" => "Evolución temporal de las cifras de creatinina y urea." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Ana Belen Martínez López, Olalla Álvarez Blanco, Augusto Luque de Pablos, María Dolores Morales San-José, Ana Rodríguez Sanchez de la Blanca" "autores" => array:5 [ 0 => array:2 [ "nombre" => "Ana Belen" "apellidos" => "Martínez López" ] 1 => array:2 [ "nombre" => "Olalla" "apellidos" => "Álvarez Blanco" ] 2 => array:2 [ "nombre" => "Augusto" "apellidos" => "Luque de Pablos" ] 3 => array:2 [ "nombre" => "María Dolores" "apellidos" => "Morales San-José" ] 4 => array:2 [ "nombre" => "Ana" "apellidos" => "Rodríguez Sanchez de la Blanca" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2013251416000250" "doi" => "10.1016/j.nefroe.2016.02.004" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2013251416000250?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0211699515001411?idApp=UINPBA000064" "url" => "/02116995/0000003600000001/v1_201602110042/S0211699515001411/v1_201602110042/es/main.assets" ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "Letter to the Editor" "titulo" => "Eculizumab for the treatment of an atypical hemolytic uremic syndrome with mutations in complement factor I and C3" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "72" "paginaFinal" => "75" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Emanuel Ferreira, Nuno Oliveira, Maria Marques, Luís Francisco, Ana Santos, Armando Carreira, Mário Campos" "autores" => array:7 [ 0 => array:4 [ "nombre" => "Emanuel" "apellidos" => "Ferreira" "email" => array:1 [ 0 => "emanuelfeferreira@gmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Nuno" "apellidos" => "Oliveira" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] ] ] 2 => array:3 [ "nombre" => "Maria" "apellidos" => "Marques" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] ] ] 3 => array:3 [ "nombre" => "Luís" "apellidos" => "Francisco" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] ] ] 4 => array:3 [ "nombre" => "Ana" "apellidos" => "Santos" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] ] ] 5 => array:3 [ "nombre" => "Armando" "apellidos" => "Carreira" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] ] ] 6 => array:3 [ "nombre" => "Mário" "apellidos" => "Campos" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "c" "identificador" => "aff0015" ] ] ] ] "afiliaciones" => array:3 [ 0 => array:3 [ "entidad" => "Servicio de Nefrología, Centro Hospitalar e Universitário de Coimbra–Hospital Geral, Coimbra, Portugal" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Servicio de Hematología, Centro Hospitalar e Universitário de Coimbra–Hospital Geral, Coimbra, Portugal" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Servicio de Nefrología, Centro Hospitalar e Universitário de Coimbra–Hospitais da Universidade de Coimbra, Coimbra, Portugal" "etiqueta" => "c" "identificador" => "aff0015" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author at: Servicio de Nefrología, Centro Hospitalar e Universitário de Coimbra–Hospital Geral., Rua do Buxo, lote 17, 3040-792 Coimbra, Portugal. Tel.: +351 916699039." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Eculizumab para el tratamiento de un síndrome urémico hemolítico atípico con mutaciones en los factores I y C3 del sistema del complemento" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 3462 "Ancho" => 2454 "Tamanyo" => 392693 ] ] "descripcion" => array:1 [ "en" => "Clinical course: laboratory data and treatment. Corticosteroid therapy was started with intravenous administration of methylprednisolone (1000mg/day for 3 days) followed by oral prednisolone and an initial dosage of 60mg/day. This dosage was maintained until the 53rd day after admission, with posterior tapering. Rituximab (arrows) was administered at a dose of 600mg (375mg/m2) on the 27th, 34th, 41st and 48th days after admission. Cyclophosphamide (arrowhead) was administered in a single dose of 1000mg on the 61st day after admission (2nd day after readmission). Eculizumab was administered at a dose of 900mg for a week for 4 weeks, started on the 158th day after admission, followed by a dosage of 1200mg 1 week later an then a maintenance dose of 1200mg every 2 weeks. This dosage is still being continued. We performed a total of 79 plasma exchange sessions. The last three laboratorial test results were done on the 270th, 340th and 466th days following first admission." ] ] ] "textoCompleto" => "Atypical hemolytic-uremic syndrome (aHUS) is a rare, life-threatening complement-mediated thrombotic microangiopathy.<a class="elsevierStyleCrossRef" href="#bib0055">1</a> Approximately half of cases have mutations in complement proteins but only 12% have 2 or more mutations.<a class="elsevierStyleCrossRef" href="#bib0060">2</a> Eculizumab is nowadays considered first-line therapy for aHUS.<a class="elsevierStyleCrossRef" href="#bib0065">3</a>A 33-year-old female with unremarkable past medical history presented with a 3-day history of decreased urine output. Physical examination showed hypertension (160/90mmHg) and lower limbs edema. Investigations revealed an acute thrombotic microangiopathy (ATM), hematuria and nephrotic proteinuria (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>). Daily plasmapheresis (PMP) was started immediately.<elsevierMultimedia ident="tbl0005"></elsevierMultimedia>Investigations for secondary causes of ATM revealed a low ADAMTS 13 activity, decreased complement C4, C3, C1q and C2 levels and positive serum cryoglobulins (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>). Considering the hypothesis of an autoimmune disorder, we started 3 daily pulses of 1000mg methylprednisolone followed by oral prednisolone.PMP was stopped on the eighteenth day of admission (D18) due to normal platelet count during 3 consecutive days (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>). On the D19 a renal biopsy was made. It showed a “thrombotic microangiopathy with acute tubular necrosis” and “deposition of IgM, C3 and C1q in the capillary wall”. Due to increased hemolytic activity, PMP was resumed on the D21. On the D27, rituximab was started to enhance immunosuppression. PMP was stopped on the D35 based on the absence of schistocytosis, hemoglobin stability and lactate dehydrogenase (LDH) normalization.<elsevierMultimedia ident="fig0005"></elsevierMultimedia>On the D50, LDH was high but hemoglobin and platelet count were stable. A state of compensated hemolysis was assumed and the patient was discharged home.Ten days later she was readmitted due to increased hemolytic activity (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>). PMP was resumed and 1000mg cyclophosphamide was given. At that time ADAMTS13 and complement C4 levels were normal but complement C3 levels remained low.A genetic screening for mutations in complement regulatory proteins was made. Two mutations were found in factor I (C. 452 A>G, pASN 151 Ser) and C3 (C193 A>C, pLys 65 Gin) proteins. The process of eculizumab acquisition was lengthy, wherefore this therapy was started only on the 98th day after readmission. At that moment we were performing one PMP session/week, LDH remained high (859U/L) and moderate renal dysfunction (creatinine 2.08mg/dL and urea 60mg/dL) and nephrotic proteinuria persisted (5.2g/24h). Eculizumab was administered at a dose of 900mg per week for 4 weeks followed by subsequent doses of 1200mg every 2 weeks since the 5th week. Complete hematologic remission was attained 2 days after eculizumab initiation. The patient was discharged home on the 105th day after readmission. Four weeks later, proteinuria was only 0.6g/24h.Currently, 10 months after first infusion, the patient remains under biweekly administration of eculizumab. Hematologic remission persists and there is a significant recover of renal function (urea 43mg/dL, creatinine 1.27mg/dL).Complement factor I (CFI) and C3 mutations account for 10% and 4% of the overall aHUS-associated mutations, respectively.<a class="elsevierStyleCrossRef" href="#bib0065">3</a> C3 mutations are among the ones with the poorest prognosis: 75% risk of death or end stage renal failure (ESRF) at 3–5 years follow up and 50% risk of recurrence.<a class="elsevierStyleCrossRef" href="#bib0065">3</a> CFI mutations have a 50–60% risk of death and ESRF at 3–5 years follow up and 10–30% risk of recurrence.<a class="elsevierStyleCrossRef" href="#bib0065">3</a>Both mutations present in our patient were previously reported.<a class="elsevierStyleCrossRefs" href="#bib0070">4,5</a> The p.Asn151Ser mutation causes a quantitative deficiency of factor I<a class="elsevierStyleCrossRef" href="#bib0070">4</a> and the p.Lys65Gin mutation weakens the affinity of C3b to complement factor H.<a class="elsevierStyleCrossRef" href="#bib0075">5</a>Despite the growing importance of eculizumab,<a class="elsevierStyleCrossRefs" href="#bib0080">6,7</a> PMP remains the mainstay of treatment while waiting for the immunoglobulin.<a class="elsevierStyleCrossRef" href="#bib0065">3</a> Nonetheless, its benefit depends on the underlying genetic defect – only 25% and 57% of those with CFI and C3 mutations, respectively, achieve remission.<a class="elsevierStyleCrossRef" href="#bib0090">8</a> In our patient, PMP was critical to prevent further progression of renal failure and the development of other systemic involvement. However, as described by Loirat,<a class="elsevierStyleCrossRef" href="#bib0060">2</a> it was unable to achieve complete and sustained remission.In our case, the confounding presence of low ADAMTS13, C4, C2 and C1q levels, the presence of cryoglobulins and the existence of immune deposits in the glomerular capillary wall led to the misdiagnosis of a thrombotic thrombocytopenic purpura secondary to an autoimmune disease. It explains the preference for glucocorticoids, rituximab and cyclophosphamide in relation to eculizumab.<a class="elsevierStyleCrossRef" href="#bib0095">9</a>Eculizumab is nowadays considered first-line therapy for aHUS.<a class="elsevierStyleCrossRef" href="#bib0065">3</a> It is a humanized monoclonal immunoglobulin IgG that targets C5 and blocks the uncontrolled generation of the cytotoxic membrane attack complex.<a class="elsevierStyleCrossRef" href="#bib0100">10</a> When we started Eculizumab, our patient was still PMP dependent despite the 79 PMP sessions. Contrariwise, complete hematologic remission was attained two days after first infusion and a remarkable recover of renal function and reduction of proteinuria was evident. These findings reinforce the benefits of eculizumab in aHUS, even in cases of severe renal involvement.In conclusion, our case highlights the diagnostic challenge of aHUS and emphasizes the notion that isolated PMP is no longer the best therapeutic option in aHUS, in which cases a prompt switch to eculizumab is mandatory.The authors declare that they have no conflicts of interest related to the contents of this article." "pdfFichero" => "main.pdf" "tienePdf" => true "multimedia" => array:2 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 3462 "Ancho" => 2454 "Tamanyo" => 392693 ] ] "descripcion" => array:1 [ "en" => "Clinical course: laboratory data and treatment. Corticosteroid therapy was started with intravenous administration of methylprednisolone (1000mg/day for 3 days) followed by oral prednisolone and an initial dosage of 60mg/day. This dosage was maintained until the 53rd day after admission, with posterior tapering. Rituximab (arrows) was administered at a dose of 600mg (375mg/m2) on the 27th, 34th, 41st and 48th days after admission. Cyclophosphamide (arrowhead) was administered in a single dose of 1000mg on the 61st day after admission (2nd day after readmission). Eculizumab was administered at a dose of 900mg for a week for 4 weeks, started on the 158th day after admission, followed by a dosage of 1200mg 1 week later an then a maintenance dose of 1200mg every 2 weeks. This dosage is still being continued. We performed a total of 79 plasma exchange sessions. The last three laboratorial test results were done on the 270th, 340th and 466th days following first admission." ] ] 1 => array:7 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "tablatextoimagen" => array:2 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " colspan="3" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">On admission</th></tr><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Variable \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Result \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Normal range \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Hemoglobin (g/dL) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">11.1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">12–16 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">White-cell count (×103/mm3) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">7.6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">4–10 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Platelet count (×103/mm3) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">36 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">150–400 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Peripheral blood smear<a class="elsevierStyleCrossRef" href="#tblfn0005">a</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">10 schistocytes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><2 schistocytes \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Haptoglobin (g/L) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><0.08 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.3–2 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Direct coombs tests \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Negative \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Negative \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Urea (mg/dL) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">114 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">15–38 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Creatinine (mg/dL) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2.9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.52–1.04 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Sodium (mmol/L) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">135 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">137–145 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Potassium (mmol/L) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3.6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3.5–5.1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Lactate dehydrogenase (U/L) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2827 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">313–618 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">c-Reactive protein (mg/dL) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><1.0 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top">URINALYSIS</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Protein (mg/dL) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1000 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Leukocytes (/HPF) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><5/c \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Red blood cells (/HPF) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">28 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><2/c \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Urinary protein to creatinine ratio (mg/mg) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">14 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><0.15 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab989344.png" ] ] 1 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " colspan="3" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Additional studies</th></tr><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Variable \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Result \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Normal range \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">C3 (g/L) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.46 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.9–1.8 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">C4 (g/L) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.02 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.1–0.4 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">CH50 (U/mL) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">13 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">23–46 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">C1q (mg/L) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">39 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">118–244 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">C1q Inhibitor (mg/L) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">197 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">180/320 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">C2 (mg/L) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">7.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">14–25 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">ADAMTS13 activity (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">7% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">40–130 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Anti-ADAMTS13 antibody (U/mL) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Negative \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><15 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Serum cryoglobulins \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Positive \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Auto-immune antibodies<a class="elsevierStyleCrossRef" href="#tblfn0010">b</a>, Pregnancy test, SPE, Tumoral markers<a class="elsevierStyleCrossRef" href="#tblfn0015">c</a>, HIV, HBV, HCV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Negative/Normal \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Blood, urine and stool cultures \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Negative \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Upper endoscopy, colonoscopy, cervical, thoracic and abdominopelvic CT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Irrelevant changes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab989343.png" ] ] ] "notaPie" => array:3 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "a" "nota" => "Peripheral blood smear was done to evaluate presence of erythrocyte fragmentation and is reported as schistocytes count in a microscopic field at 100× magnification." ] 1 => array:3 [ "identificador" => "tblfn0010" "etiqueta" => "b" "nota" => "Antinuclear antibodies, extractable nuclear antigens, anti-neutrophil cytoplasmic antibodies, glomerular basement membrane, rheumatoid factor, cyclic citrullinated peptide, anticardiolipin/anti-β2-glycoprotein, Lupus anticoagulant." ] 2 => array:3 [ "identificador" => "tblfn0015" "etiqueta" => "c" "nota" => "Carcinoembryonic antigen, carbohydrate antigen 19-9, α-fetoprotein, cancer antigen 125, neuron-specific enolase, NSE. Abbreviations: ADAMTS13; a disintegrin and metalloproteinase with a thrombospondin type 1 motif; member 13. CT; computerized tomography. HBV; hepatitis B virus. HCV; hepatitis C virus. HIV; human immunodeficiency virus. SPE; serum protein electrophoresis." ] ] ] "descripcion" => array:1 [ "en" => "Laboratorial results on admission and additional studies to establish the cause of the thrombotic microangiopathy." ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:10 [ 0 => array:3 [ "identificador" => "bib0055" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of atypical uraemic syndrome in the era of eculizumab" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "V. Fremeaux-Bacchi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/ckj/sfr177" "Revista" => array:6 [ "tituloSerie" => "Clin Kidney J" "fecha" => "2012" "volumen" => "5" "paginaInicial" => "4" "paginaFinal" => "6" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26069738" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0060" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Atypical hemolytic uremic syndrome" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "C. Loirat" 1 => "V. Frémeaux-Bacchi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/1750-1172-6-60" "Revista" => array:5 [ "tituloSerie" => "Orphanet J Rare Dis" "fecha" => "2011" "volumen" => "6" "paginaInicial" => "60" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21902819" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0065" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Actualización en síndrome hemolítico urémico atípico: diagnóstico y tratamiento. Documento de consenso" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.M. Campistol" 1 => "M. Arias" 2 => "G. Ariceta" 3 => "M. Blasco" 4 => "M. Espinosa" 5 => "J.M. Grinyó" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3265/Nefrologia.pre2012.Nov.11781" "Revista" => array:6 [ "tituloSerie" => "Nefrologia" "fecha" => "2013" "volumen" => "33" "paginaInicial" => "27" "paginaFinal" => "45" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23364625" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0070" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "F. Bienaime" 1 => "M.A. Dragon-Durey" 2 => "C.H. Regnier" 3 => "S.C. Nilsson" 4 => "W.H. Kwan" 5 => "J. Blouin" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/ki.2009.472" "Revista" => array:6 [ "tituloSerie" => "Kidney Int" "fecha" => "2010" "volumen" => "77" "paginaInicial" => "339" "paginaFinal" => "349" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20016463" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0075" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Novel C3 mutation p.Lys65Gln in aHUS affects complement factor H binding" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "E. Volokhina" 1 => "D. Westra" 2 => "X. Xue" 3 => "P. Gros" 4 => "N. van de Kar" 5 => "L. van den Heuvel" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00467-012-2183-z" "Revista" => array:6 [ "tituloSerie" => "Pediatr Nephrol" "fecha" => "2012" "volumen" => "27" "paginaInicial" => "1519" "paginaFinal" => "1524" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22669319" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0080" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "J. Rathbone" 1 => "E. Kaltenthaler" 2 => "A. Richards" 3 => "P. Tappenden" 4 => "A. Bessey" 5 => "A. Cantrell" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/bmjopen-2013-003573" "Revista" => array:5 [ "tituloSerie" => "BMJ Open" "fecha" => "2013" "volumen" => "3" "paginaInicial" => "e003573" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24189082" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0085" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C.M. Legendre" 1 => "C. Licht" 2 => "P. Muus" 3 => "L.A. Greenbaum" 4 => "S. Babu" 5 => "C. Bedrosian" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1208981" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2013" "volumen" => "368" "paginaInicial" => "2169" "paginaFinal" => "2181" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23738544" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0090" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Noris" 1 => "J. Caprioli" 2 => "E. Bresin" 3 => "C. Mossali" 4 => "G. Pianetti" 5 => "S. Gamba" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2215/CJN.02210310" "Revista" => array:6 [ "tituloSerie" => "Clin J Am Soc Nephrol" "fecha" => "2010" "volumen" => "5" "paginaInicial" => "1844" "paginaFinal" => "1859" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20595690" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0095" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "A.A. Kaplan" 1 => "J.N. George" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "Uptodate" "fecha" => "2014" ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0100" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Eculizumab: a review of its use in atypical haemolytic uraemic syndrome" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "G.M. Keating" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s40265-013-0147-7" "Revista" => array:6 [ "tituloSerie" => "Drugs" "fecha" => "2013" "volumen" => "73" "paginaInicial" => "2053" "paginaFinal" => "2066" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24249647" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/02116995/0000003600000001/v1_201602110042/S0211699515001538/v1_201602110042/en/main.assets" "Apartado" => array:4 [ "identificador" => "48186" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Cartas al Director" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/02116995/0000003600000001/v1_201602110042/S0211699515001538/v1_201602110042/en/main.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0211699515001538?idApp=UINPBA000064"]

Estadísticas

Letter to the Editor

Eculizumab for the treatment of an atypical hemolytic uremic syndrome with mutations in complement factor I and C3

Eculizumab para el tratamiento de un síndrome urémico hemolítico atípico con mutaciones en los factores I y C3 del sistema del complemento

Emanuel Ferreiraa,

Autor para correspondencia

emanuelfeferreira@gmail.com

Corresponding author at: Servicio de Nefrología, Centro Hospitalar e Universitário de Coimbra–Hospital Geral., Rua do Buxo, lote 17, 3040-792 Coimbra, Portugal. Tel.: +351 916699039.

, Nuno Oliveiraa, Maria Marquesa, Luís Franciscob, Ana Santosa, Armando Carreiraa, Mário Camposc

a Servicio de Nefrología, Centro Hospitalar e Universitário de Coimbra–Hospital Geral, Coimbra, Portugal

b Servicio de Hematología, Centro Hospitalar e Universitário de Coimbra–Hospital Geral, Coimbra, Portugal

c Servicio de Nefrología, Centro Hospitalar e Universitário de Coimbra–Hospitais da Universidade de Coimbra, Coimbra, Portugal

Leído

10828

Veces
se ha leído el artículo

2686

Total PDF

8142

Total HTML

Compartir estadísticas

 array:24 [
  "pii" => "S0211699515001538"
  "issn" => "02116995"
  "doi" => "10.1016/j.nefro.2015.07.007"
  "estado" => "S300"
  "fechaPublicacion" => "2016-01-01"
  "aid" => "101"
  "copyright" => "Sociedad Espa&#241;ola de Nefrolog&#237;a"
  "copyrightAnyo" => "2015"
  "documento" => "simple-article"
  "crossmark" => 0
  "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
  "subdocumento" => "cor"
  "cita" => "Nefrologia. 2016;36:72-5"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 5671
    "formatos" => array:3 [
      "EPUB" => 305
      "HTML" => 4601
      "PDF" => 765
    ]
  ]
  "itemSiguiente" => array:19 [
    "pii" => "S0211699515001381"
    "issn" => "02116995"
    "doi" => "10.1016/j.nefro.2015.08.003"
    "estado" => "S300"
    "fechaPublicacion" => "2016-01-01"
    "aid" => "86"
    "copyright" => "Sociedad Espa&#241;ola de Nefrolog&#237;a"
    "documento" => "simple-article"
    "crossmark" => 0
    "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
    "subdocumento" => "cor"
    "cita" => "Nefrologia. 2016;36:75-6"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 5482
      "formatos" => array:3 [
        "EPUB" => 387
        "HTML" => 4255
        "PDF" => 840
      ]
    ]
    "en" => array:10 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>"
      "titulo" => "Methylmalonic acidemia with emergency hypertension"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "75"
          "paginaFinal" => "76"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Acidemia metilmal&#243;nica con hipertensi&#243;n de emergencia"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Bahareh Yaghmaei, Parastoo Rostami, Farnaz Najmi Varzaneh, Behdad Gharib, Behnaz Bazargani, Nima Rezaei"
          "autores" => array:6 [
            0 => array:2 [
              "nombre" => "Bahareh"
              "apellidos" => "Yaghmaei"
            ]
            1 => array:2 [
              "nombre" => "Parastoo"
              "apellidos" => "Rostami"
            ]
            2 => array:2 [
              "nombre" => "Farnaz Najmi"
              "apellidos" => "Varzaneh"
            ]
            3 => array:2 [
              "nombre" => "Behdad"
              "apellidos" => "Gharib"
            ]
            4 => array:2 [
              "nombre" => "Behnaz"
              "apellidos" => "Bazargani"
            ]
            5 => array:2 [
              "nombre" => "Nima"
              "apellidos" => "Rezaei"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0211699515001381?idApp=UINPBA000064"
    "url" => "/02116995/0000003600000001/v1_201602110042/S0211699515001381/v1_201602110042/en/main.assets"
  ]
  "itemAnterior" => array:20 [
    "pii" => "S0211699515001411"
    "issn" => "02116995"
    "doi" => "10.1016/j.nefro.2015.09.003"
    "estado" => "S300"
    "fechaPublicacion" => "2016-01-01"
    "aid" => "89"
    "copyright" => "Sociedad Espa&#241;ola de Nefrolog&#237;a"
    "documento" => "simple-article"
    "crossmark" => 0
    "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
    "subdocumento" => "crp"
    "cita" => "Nefrologia. 2016;36:69-71"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 10984
      "formatos" => array:3 [
        "EPUB" => 346
        "HTML" => 9417
        "PDF" => 1221
      ]
    ]
    "es" => array:11 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Carta al Director&#58; Comentarios breves sobre casos cl&#237;nicos</span>"
      "titulo" => "Nefritis intersticial aguda por ibuprofeno en poblaci&#243;n pedi&#225;trica"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "69"
          "paginaFinal" => "71"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Ibuprofen-induced acute interstitial nephritis in the paediatric population"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Figura 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 1974
              "Ancho" => 1658
              "Tamanyo" => 175863
            ]
          ]
          "descripcion" => array:1 [
            "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Evoluci&#243;n temporal de las cifras de creatinina y urea&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Ana Belen Mart&#237;nez L&#243;pez, Olalla &#193;lvarez Blanco, Augusto Luque de Pablos, Mar&#237;a Dolores Morales San-Jos&#233;, Ana Rodr&#237;guez Sanchez de la Blanca"
          "autores" => array:5 [
            0 => array:2 [
              "nombre" => "Ana Belen"
              "apellidos" => "Mart&#237;nez L&#243;pez"
            ]
            1 => array:2 [
              "nombre" => "Olalla"
              "apellidos" => "&#193;lvarez Blanco"
            ]
            2 => array:2 [
              "nombre" => "Augusto"
              "apellidos" => "Luque de Pablos"
            ]
            3 => array:2 [
              "nombre" => "Mar&#237;a Dolores"
              "apellidos" => "Morales San-Jos&#233;"
            ]
            4 => array:2 [
              "nombre" => "Ana"
              "apellidos" => "Rodr&#237;guez Sanchez de la Blanca"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S2013251416000250"
        "doi" => "10.1016/j.nefroe.2016.02.004"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2013251416000250?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0211699515001411?idApp=UINPBA000064"
    "url" => "/02116995/0000003600000001/v1_201602110042/S0211699515001411/v1_201602110042/es/main.assets"
  ]
  "en" => array:13 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>"
    "titulo" => "Eculizumab for the treatment of an atypical hemolytic uremic syndrome with mutations in complement factor I and C3"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "72"
        "paginaFinal" => "75"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "Emanuel Ferreira, Nuno Oliveira, Maria Marques, Lu&#237;s Francisco, Ana Santos, Armando Carreira, M&#225;rio Campos"
        "autores" => array:7 [
          0 => array:4 [
            "nombre" => "Emanuel"
            "apellidos" => "Ferreira"
            "email" => array:1 [
              0 => "emanuelfeferreira&#64;gmail&#46;com"
            ]
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "Nuno"
            "apellidos" => "Oliveira"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "Maria"
            "apellidos" => "Marques"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "Lu&#237;s"
            "apellidos" => "Francisco"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          4 => array:3 [
            "nombre" => "Ana"
            "apellidos" => "Santos"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
          5 => array:3 [
            "nombre" => "Armando"
            "apellidos" => "Carreira"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
          6 => array:3 [
            "nombre" => "M&#225;rio"
            "apellidos" => "Campos"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:3 [
          0 => array:3 [
            "entidad" => "Servicio de Nefrolog&#237;a&#44; Centro Hospitalar e Universit&#225;rio de Coimbra&#8211;Hospital Geral&#44; Coimbra&#44; Portugal"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Servicio de Hematolog&#237;a&#44; Centro Hospitalar e Universit&#225;rio de Coimbra&#8211;Hospital Geral&#44; Coimbra&#44; Portugal"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
          2 => array:3 [
            "entidad" => "Servicio de Nefrolog&#237;a&#44; Centro Hospitalar e Universit&#225;rio de Coimbra&#8211;Hospitais da Universidade de Coimbra&#44; Coimbra&#44; Portugal"
            "etiqueta" => "c"
            "identificador" => "aff0015"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "<span class="elsevierStyleItalic">Corresponding author at</span>&#58; Servicio de Nefrolog&#237;a&#44; Centro Hospitalar e Universit&#225;rio de Coimbra&#8211;Hospital Geral&#46;&#44; Rua do Buxo&#44; lote 17&#44; 3040-792 Coimbra&#44; Portugal&#46; Tel&#46;&#58; &#43;351 916699039&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Eculizumab para el tratamiento de un s&#237;ndrome ur&#233;mico hemol&#237;tico at&#237;pico con mutaciones en los factores I y C3 del sistema del complemento"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Fig&#46; 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 3462
            "Ancho" => 2454
            "Tamanyo" => 392693
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Clinical course&#58; laboratory data and treatment&#46; Corticosteroid therapy was started with intravenous administration of methylprednisolone &#40;1000<span class="elsevierStyleHsp" style=""></span>mg&#47;day for 3 days&#41; followed by oral prednisolone and an initial dosage of 60<span class="elsevierStyleHsp" style=""></span>mg&#47;day&#46; This dosage was maintained until the 53rd day after admission&#44; with posterior tapering&#46; Rituximab &#40;arrows&#41; was administered at a dose of 600<span class="elsevierStyleHsp" style=""></span>mg &#40;375<span class="elsevierStyleHsp" style=""></span>mg&#47;m2&#41; on the 27th&#44; 34th&#44; 41st and 48th days after admission&#46; Cyclophosphamide &#40;arrowhead&#41; was administered in a single dose of 1000<span class="elsevierStyleHsp" style=""></span>mg on the 61st day after admission &#40;2nd day after readmission&#41;&#46; Eculizumab was administered at a dose of 900<span class="elsevierStyleHsp" style=""></span>mg for a week for 4 weeks&#44; started on the 158th day after admission&#44; followed by a dosage of 1200<span class="elsevierStyleHsp" style=""></span>mg 1 week later an then a maintenance dose of 1200<span class="elsevierStyleHsp" style=""></span>mg every 2 weeks&#46; This dosage is still being continued&#46; We performed a total of 79 plasma exchange sessions&#46; The last three laboratorial test results were done on the 270th&#44; 340th and 466th days following first admission&#46;</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Atypical hemolytic-uremic syndrome &#40;aHUS&#41; is a rare&#44; life-threatening complement-mediated thrombotic microangiopathy&#46;<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">1</span></a> Approximately half of cases have mutations in complement proteins but only 12&#37; have 2 or more mutations&#46;<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">2</span></a> Eculizumab is nowadays considered first-line therapy for aHUS&#46;<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">3</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">A 33-year-old female with unremarkable past medical history presented with a 3-day history of decreased urine output&#46; Physical examination showed hypertension &#40;160&#47;90<span class="elsevierStyleHsp" style=""></span>mmHg&#41; and lower limbs edema&#46; Investigations revealed an acute thrombotic microangiopathy &#40;ATM&#41;&#44; hematuria and nephrotic proteinuria &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41;&#46; Daily plasmapheresis &#40;PMP&#41; was started immediately&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0015" class="elsevierStylePara elsevierViewall">Investigations for secondary causes of ATM revealed a low ADAMTS 13 activity&#44; decreased complement C4&#44; C3&#44; C1q and C2 levels and positive serum cryoglobulins &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41;&#46; Considering the hypothesis of an autoimmune disorder&#44; we started 3 daily pulses of 1000<span class="elsevierStyleHsp" style=""></span>mg methylprednisolone followed by oral prednisolone&#46;</p><p id="par0020" class="elsevierStylePara elsevierViewall">PMP was stopped on the eighteenth day of admission &#40;D18&#41; due to normal platelet count during 3 consecutive days &#40;<a class="elsevierStyleCrossRef" href="#fig0005">Fig&#46; 1</a>&#41;&#46; On the D19 a renal biopsy was made&#46; It showed a &#8220;thrombotic microangiopathy with acute tubular necrosis&#8221; and &#8220;deposition of IgM&#44; C3 and C1q in the capillary wall&#8221;&#46; Due to increased hemolytic activity&#44; PMP was resumed on the D21&#46; On the D27&#44; rituximab was started to enhance immunosuppression&#46; PMP was stopped on the D35 based on the absence of schistocytosis&#44; hemoglobin stability and lactate dehydrogenase &#40;LDH&#41; normalization&#46;</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0025" class="elsevierStylePara elsevierViewall">On the D50&#44; LDH was high but hemoglobin and platelet count were stable&#46; A state of compensated hemolysis was assumed and the patient was discharged home&#46;</p><p id="par0030" class="elsevierStylePara elsevierViewall">Ten days later she was readmitted due to increased hemolytic activity &#40;<a class="elsevierStyleCrossRef" href="#fig0005">Fig&#46; 1</a>&#41;&#46; PMP was resumed and 1000<span class="elsevierStyleHsp" style=""></span>mg cyclophosphamide was given&#46; At that time ADAMTS13 and complement C4 levels were normal but complement C3 levels remained low&#46;</p><p id="par0035" class="elsevierStylePara elsevierViewall">A genetic screening for mutations in complement regulatory proteins was made&#46; Two mutations were found in factor I &#40;C&#46; 452 A&#62;G&#44; pASN 151 Ser&#41; and C3 &#40;C193 A<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>C&#44; pLys 65 Gin&#41; proteins&#46; The process of eculizumab acquisition was lengthy&#44; wherefore this therapy was started only on the 98th day after readmission&#46; At that moment we were performing one PMP session&#47;week&#44; LDH remained high &#40;859<span class="elsevierStyleHsp" style=""></span>U&#47;L&#41; and moderate renal dysfunction &#40;creatinine 2&#46;08<span class="elsevierStyleHsp" style=""></span>mg&#47;dL and urea 60<span class="elsevierStyleHsp" style=""></span>mg&#47;dL&#41; and nephrotic proteinuria persisted &#40;5&#46;2<span class="elsevierStyleHsp" style=""></span>g&#47;24<span class="elsevierStyleHsp" style=""></span>h&#41;&#46; Eculizumab was administered at a dose of 900<span class="elsevierStyleHsp" style=""></span>mg per week for 4 weeks followed by subsequent doses of 1200<span class="elsevierStyleHsp" style=""></span>mg every 2 weeks since the 5th week&#46; Complete hematologic remission was attained 2 days after eculizumab initiation&#46; The patient was discharged home on the 105th day after readmission&#46; Four weeks later&#44; proteinuria was only 0&#46;6<span class="elsevierStyleHsp" style=""></span>g&#47;24<span class="elsevierStyleHsp" style=""></span>h&#46;</p><p id="par0040" class="elsevierStylePara elsevierViewall">Currently&#44; 10 months after first infusion&#44; the patient remains under biweekly administration of eculizumab&#46; Hematologic remission persists and there is a significant recover of renal function &#40;urea 43<span class="elsevierStyleHsp" style=""></span>mg&#47;dL&#44; creatinine 1&#46;27<span class="elsevierStyleHsp" style=""></span>mg&#47;dL&#41;&#46;</p><p id="par0045" class="elsevierStylePara elsevierViewall">Complement factor I &#40;CFI&#41; and C3 mutations account for 10&#37; and 4&#37; of the overall aHUS-associated mutations&#44; respectively&#46;<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">3</span></a> C3 mutations are among the ones with the poorest prognosis&#58; 75&#37; risk of death or end stage renal failure &#40;ESRF&#41; at 3&#8211;5 years follow up and 50&#37; risk of recurrence&#46;<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">3</span></a> CFI mutations have a 50&#8211;60&#37; risk of death and ESRF at 3&#8211;5 years follow up and 10&#8211;30&#37; risk of recurrence&#46;<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">3</span></a></p><p id="par0050" class="elsevierStylePara elsevierViewall">Both mutations present in our patient were previously reported&#46;<a class="elsevierStyleCrossRefs" href="#bib0070"><span class="elsevierStyleSup">4&#44;5</span></a> The p&#46;Asn151Ser mutation causes a quantitative deficiency of factor I<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">4</span></a> and the p&#46;Lys65Gin mutation weakens the affinity of C3b to complement factor H&#46;<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">5</span></a></p><p id="par0055" class="elsevierStylePara elsevierViewall">Despite the growing importance of eculizumab&#44;<a class="elsevierStyleCrossRefs" href="#bib0080"><span class="elsevierStyleSup">6&#44;7</span></a> PMP remains the mainstay of treatment while waiting for the immunoglobulin&#46;<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">3</span></a> Nonetheless&#44; its benefit depends on the underlying genetic defect &#8211; only 25&#37; and 57&#37; of those with CFI and C3 mutations&#44; respectively&#44; achieve remission&#46;<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">8</span></a> In our patient&#44; PMP was critical to prevent further progression of renal failure and the development of other systemic involvement&#46; However&#44; as described by Loirat&#44;<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">2</span></a> it was unable to achieve complete and sustained remission&#46;</p><p id="par0060" class="elsevierStylePara elsevierViewall">In our case&#44; the confounding presence of low ADAMTS13&#44; C4&#44; C2 and C1q levels&#44; the presence of cryoglobulins and the existence of immune deposits in the glomerular capillary wall led to the misdiagnosis of a thrombotic thrombocytopenic purpura secondary to an autoimmune disease&#46; It explains the preference for glucocorticoids&#44; rituximab and cyclophosphamide in relation to eculizumab&#46;<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">9</span></a></p><p id="par0065" class="elsevierStylePara elsevierViewall">Eculizumab is nowadays considered first-line therapy for aHUS&#46;<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">3</span></a> It is a humanized monoclonal immunoglobulin IgG that targets C5 and blocks the uncontrolled generation of the cytotoxic membrane attack complex&#46;<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">10</span></a> When we started Eculizumab&#44; our patient was still PMP dependent despite the 79 PMP sessions&#46; Contrariwise&#44; complete hematologic remission was attained two days after first infusion and a remarkable recover of renal function and reduction of proteinuria was evident&#46; These findings reinforce the benefits of eculizumab in aHUS&#44; even in cases of severe renal involvement&#46;</p><p id="par0070" class="elsevierStylePara elsevierViewall">In conclusion&#44; our case highlights the diagnostic challenge of aHUS and emphasizes the notion that isolated PMP is no longer the best therapeutic option in aHUS&#44; in which cases a prompt switch to eculizumab is mandatory&#46;</p><p id="par0075" class="elsevierStylePara elsevierViewall">The authors declare that they have no conflicts of interest related to the contents of this article&#46;</p></span>"
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "multimedia" => array:2 [
      0 => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Fig&#46; 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 3462
            "Ancho" => 2454
            "Tamanyo" => 392693
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Clinical course&#58; laboratory data and treatment&#46; Corticosteroid therapy was started with intravenous administration of methylprednisolone &#40;1000<span class="elsevierStyleHsp" style=""></span>mg&#47;day for 3 days&#41; followed by oral prednisolone and an initial dosage of 60<span class="elsevierStyleHsp" style=""></span>mg&#47;day&#46; This dosage was maintained until the 53rd day after admission&#44; with posterior tapering&#46; Rituximab &#40;arrows&#41; was administered at a dose of 600<span class="elsevierStyleHsp" style=""></span>mg &#40;375<span class="elsevierStyleHsp" style=""></span>mg&#47;m2&#41; on the 27th&#44; 34th&#44; 41st and 48th days after admission&#46; Cyclophosphamide &#40;arrowhead&#41; was administered in a single dose of 1000<span class="elsevierStyleHsp" style=""></span>mg on the 61st day after admission &#40;2nd day after readmission&#41;&#46; Eculizumab was administered at a dose of 900<span class="elsevierStyleHsp" style=""></span>mg for a week for 4 weeks&#44; started on the 158th day after admission&#44; followed by a dosage of 1200<span class="elsevierStyleHsp" style=""></span>mg 1 week later an then a maintenance dose of 1200<span class="elsevierStyleHsp" style=""></span>mg every 2 weeks&#46; This dosage is still being continued&#46; We performed a total of 79 plasma exchange sessions&#46; The last three laboratorial test results were done on the 270th&#44; 340th and 466th days following first admission&#46;</p>"
        ]
      ]
      1 => array:7 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:2 [
          "tablatextoimagen" => array:2 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " colspan="3" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">On admission</th></tr><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Variable&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Result&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Normal range&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Hemoglobin &#40;g&#47;dL&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">11&#46;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12&#8211;16&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">White-cell count &#40;&#215;10<span class="elsevierStyleSup">3</span>&#47;mm<span class="elsevierStyleSup">3</span>&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">7&#46;6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">4&#8211;10&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Platelet count &#40;&#215;10<span class="elsevierStyleSup">3</span>&#47;mm<span class="elsevierStyleSup">3</span>&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">36&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">150&#8211;400&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Peripheral blood smear<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">10 schistocytes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#60;2 schistocytes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Haptoglobin &#40;g&#47;L&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#60;0&#46;08&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&#46;3&#8211;2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Direct coombs tests&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Negative&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Negative&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Urea &#40;mg&#47;dL&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">114&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">15&#8211;38&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Creatinine &#40;mg&#47;dL&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2&#46;9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&#46;52&#8211;1&#46;04&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Sodium &#40;mmol&#47;L&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">135&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">137&#8211;145&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Potassium &#40;mmol&#47;L&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3&#46;6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3&#46;5&#8211;5&#46;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Lactate dehydrogenase &#40;U&#47;L&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2827&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">313&#8211;618&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">c-Reactive protein &#40;mg&#47;dL&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&#46;6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#60;1&#46;0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="3" align="left" valign="top"><span class="elsevierStyleItalic">URINALYSIS</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Protein &#40;mg&#47;dL&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1000&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Leukocytes &#40;&#47;HPF&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#60;5&#47;c&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Red blood cells &#40;&#47;HPF&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">28&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#60;2&#47;c&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Urinary protein to creatinine ratio &#40;mg&#47;mg&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">14&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#60;0&#46;15&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab989344.png"
              ]
            ]
            1 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " colspan="3" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Additional studies</th></tr><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Variable&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Result&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Normal range&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">C3 &#40;g&#47;L&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&#46;46&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&#46;9&#8211;1&#46;8&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">C4 &#40;g&#47;L&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&#46;02&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&#46;1&#8211;0&#46;4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">CH50 &#40;U&#47;mL&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">13&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">23&#8211;46&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">C1q &#40;mg&#47;L&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">39&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">118&#8211;244&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">C1q Inhibitor &#40;mg&#47;L&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">197&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">180&#47;320&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">C2 &#40;mg&#47;L&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">7&#46;2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">14&#8211;25&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">ADAMTS13 activity &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">7&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">40&#8211;130&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Anti-ADAMTS13 antibody &#40;U&#47;mL&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Negative&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#60;15&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Serum cryoglobulins&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Positive&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Auto-immune antibodies<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a>&#44; Pregnancy test&#44; SPE&#44; Tumoral markers<a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">c</span></a>&#44; HIV&#44; HBV&#44; HCV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Negative&#47;Normal&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Blood&#44; urine and stool cultures&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Negative&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Upper endoscopy&#44; colonoscopy&#44; cervical&#44; thoracic and abdominopelvic CT&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Irrelevant changes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab989343.png"
              ]
            ]
          ]
          "notaPie" => array:3 [
            0 => array:3 [
              "identificador" => "tblfn0005"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Peripheral blood smear was done to evaluate presence of erythrocyte fragmentation and is reported as schistocytes count in a microscopic field at 100&#215; magnification&#46;</p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0010"
              "etiqueta" => "b"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0010">Antinuclear antibodies&#44; extractable nuclear antigens&#44; anti-neutrophil cytoplasmic antibodies&#44; glomerular basement membrane&#44; rheumatoid factor&#44; cyclic citrullinated peptide&#44; anticardiolipin&#47;anti-&#946;2-glycoprotein&#44; Lupus anticoagulant&#46;</p>"
            ]
            2 => array:3 [
              "identificador" => "tblfn0015"
              "etiqueta" => "c"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0015">Carcinoembryonic antigen&#44; carbohydrate antigen 19-9&#44; &#945;-fetoprotein&#44; cancer antigen 125&#44; neuron-specific enolase&#44; NSE&#46;</p> <p class="elsevierStyleNotepara" id="npar0020"><span class="elsevierStyleItalic">Abbreviations</span>&#58; ADAMTS13&#59; a disintegrin and metalloproteinase with a thrombospondin type 1 motif&#59; member 13&#46; CT&#59; computerized tomography&#46; HBV&#59; hepatitis B virus&#46; HCV&#59; hepatitis C virus&#46; HIV&#59; human immunodeficiency virus&#46; SPE&#59; serum protein electrophoresis&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Laboratorial results on admission and additional studies to establish the cause of the thrombotic microangiopathy&#46;</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0005"
          "bibliografiaReferencia" => array:10 [
            0 => array:3 [
              "identificador" => "bib0055"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of atypical uraemic syndrome in the era of eculizumab"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "V&#46; Fremeaux-Bacchi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/ckj/sfr177"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Kidney J"
                        "fecha" => "2012"
                        "volumen" => "5"
                        "paginaInicial" => "4"
                        "paginaFinal" => "6"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26069738"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0060"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Atypical hemolytic uremic syndrome"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "C&#46; Loirat"
                            1 => "V&#46; Fr&#233;meaux-Bacchi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1186/1750-1172-6-60"
                      "Revista" => array:5 [
                        "tituloSerie" => "Orphanet J Rare Dis"
                        "fecha" => "2011"
                        "volumen" => "6"
                        "paginaInicial" => "60"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21902819"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0065"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Actualizaci&#243;n en s&#237;ndrome hemol&#237;tico ur&#233;mico at&#237;pico&#58; diagn&#243;stico y tratamiento&#46; Documento de consenso"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;M&#46; Campistol"
                            1 => "M&#46; Arias"
                            2 => "G&#46; Ariceta"
                            3 => "M&#46; Blasco"
                            4 => "M&#46; Espinosa"
                            5 => "J&#46;M&#46; Griny&#243;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3265/Nefrologia.pre2012.Nov.11781"
                      "Revista" => array:6 [
                        "tituloSerie" => "Nefrologia"
                        "fecha" => "2013"
                        "volumen" => "33"
                        "paginaInicial" => "27"
                        "paginaFinal" => "45"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23364625"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0070"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "F&#46; Bienaime"
                            1 => "M&#46;A&#46; Dragon-Durey"
                            2 => "C&#46;H&#46; Regnier"
                            3 => "S&#46;C&#46; Nilsson"
                            4 => "W&#46;H&#46; Kwan"
                            5 => "J&#46; Blouin"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1038/ki.2009.472"
                      "Revista" => array:6 [
                        "tituloSerie" => "Kidney Int"
                        "fecha" => "2010"
                        "volumen" => "77"
                        "paginaInicial" => "339"
                        "paginaFinal" => "349"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20016463"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0075"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Novel C3 mutation p&#46;Lys65Gln in aHUS affects complement factor H binding"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "E&#46; Volokhina"
                            1 => "D&#46; Westra"
                            2 => "X&#46; Xue"
                            3 => "P&#46; Gros"
                            4 => "N&#46; van de Kar"
                            5 => "L&#46; van den Heuvel"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s00467-012-2183-z"
                      "Revista" => array:6 [
                        "tituloSerie" => "Pediatr Nephrol"
                        "fecha" => "2012"
                        "volumen" => "27"
                        "paginaInicial" => "1519"
                        "paginaFinal" => "1524"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22669319"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0080"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A systematic review of eculizumab for atypical haemolytic uraemic syndrome &#40;aHUS&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "J&#46; Rathbone"
                            1 => "E&#46; Kaltenthaler"
                            2 => "A&#46; Richards"
                            3 => "P&#46; Tappenden"
                            4 => "A&#46; Bessey"
                            5 => "A&#46; Cantrell"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/bmjopen-2013-003573"
                      "Revista" => array:5 [
                        "tituloSerie" => "BMJ Open"
                        "fecha" => "2013"
                        "volumen" => "3"
                        "paginaInicial" => "e003573"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24189082"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0085"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "C&#46;M&#46; Legendre"
                            1 => "C&#46; Licht"
                            2 => "P&#46; Muus"
                            3 => "L&#46;A&#46; Greenbaum"
                            4 => "S&#46; Babu"
                            5 => "C&#46; Bedrosian"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1208981"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2013"
                        "volumen" => "368"
                        "paginaInicial" => "2169"
                        "paginaFinal" => "2181"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23738544"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0090"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46; Noris"
                            1 => "J&#46; Caprioli"
                            2 => "E&#46; Bresin"
                            3 => "C&#46; Mossali"
                            4 => "G&#46; Pianetti"
                            5 => "S&#46; Gamba"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.2215/CJN.02210310"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin J Am Soc Nephrol"
                        "fecha" => "2010"
                        "volumen" => "5"
                        "paginaInicial" => "1844"
                        "paginaFinal" => "1859"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20595690"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0095"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "A&#46;A&#46; Kaplan"
                            1 => "J&#46;N&#46; George"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:2 [
                        "tituloSerie" => "Uptodate"
                        "fecha" => "2014"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0100"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Eculizumab&#58; a review of its use in atypical haemolytic uraemic syndrome"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "G&#46;M&#46; Keating"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s40265-013-0147-7"
                      "Revista" => array:6 [
                        "tituloSerie" => "Drugs"
                        "fecha" => "2013"
                        "volumen" => "73"
                        "paginaInicial" => "2053"
                        "paginaFinal" => "2066"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24249647"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/02116995/0000003600000001/v1_201602110042/S0211699515001538/v1_201602110042/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "48186"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Cartas al Director"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/02116995/0000003600000001/v1_201602110042/S0211699515001538/v1_201602110042/en/main.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0211699515001538?idApp=UINPBA000064"
]

Información del artículo

ISSN: 02116995
Idioma original: Inglés

DOI:10.1016/j.nefro.2015.07.007

Datos actualizados diariamente

año/Mes	Html	Pdf	Total

2024 Noviembre	12	10	22
2024 Octubre	74	38	112
2024 Septiembre	74	36	110
2024 Agosto	93	55	148
2024 Julio	55	26	81
2024 Junio	75	38	113
2024 Mayo	81	31	112
2024 Abril	92	42	134
2024 Marzo	67	30	97
2024 Febrero	87	43	130
2024 Enero	63	25	88
2023 Diciembre	55	26	81
2023 Noviembre	65	35	100
2023 Octubre	71	40	111
2023 Septiembre	47	33	80
2023 Agosto	57	32	89
2023 Julio	66	26	92
2023 Junio	94	17	111
2023 Mayo	93	30	123
2023 Abril	60	12	72
2023 Marzo	101	27	128
2023 Febrero	64	21	85
2023 Enero	70	27	97
2022 Diciembre	75	38	113
2022 Noviembre	57	37	94
2022 Octubre	88	40	128
2022 Septiembre	64	36	100
2022 Agosto	55	53	108
2022 Julio	54	54	108
2022 Junio	33	37	70
2022 Mayo	61	49	110
2022 Abril	69	59	128
2022 Marzo	67	44	111
2022 Febrero	43	45	88
2022 Enero	42	36	78
2021 Diciembre	42	38	80
2021 Noviembre	38	42	80
2021 Octubre	54	54	108
2021 Septiembre	35	32	67
2021 Agosto	36	38	74
2021 Julio	44	38	82
2021 Junio	49	21	70
2021 Mayo	57	34	91
2021 Abril	104	67	171
2021 Marzo	84	34	118
2021 Febrero	83	24	107
2021 Enero	58	30	88
2020 Diciembre	59	23	82
2020 Noviembre	41	24	65
2020 Octubre	43	25	68
2020 Septiembre	46	31	77
2020 Agosto	57	30	87
2020 Julio	55	9	64
2020 Junio	61	23	84
2020 Mayo	66	20	86
2020 Abril	43	25	68
2020 Marzo	41	19	60
2020 Febrero	48	23	71
2020 Enero	60	24	84
2019 Diciembre	46	31	77
2019 Noviembre	57	37	94
2019 Octubre	52	21	73
2019 Septiembre	51	18	69
2019 Agosto	44	25	69
2019 Julio	46	26	72
2019 Junio	51	40	91
2019 Mayo	44	31	75
2019 Abril	77	24	101
2019 Marzo	58	24	82
2019 Febrero	46	20	66
2019 Enero	52	20	72
2018 Diciembre	152	43	195
2018 Noviembre	223	20	243
2018 Octubre	228	20	248
2018 Septiembre	92	15	107
2018 Agosto	69	10	79
2018 Julio	64	11	75
2018 Junio	95	11	106
2018 Mayo	112	10	122
2018 Abril	164	12	176
2018 Marzo	124	12	136
2018 Febrero	165	9	174
2018 Enero	82	7	89
2017 Diciembre	143	14	157
2017 Noviembre	83	13	96
2017 Octubre	52	6	58
2017 Septiembre	43	14	57
2017 Agosto	56	11	67
2017 Julio	56	19	75
2017 Junio	50	24	74
2017 Mayo	62	19	81
2017 Abril	45	7	52
2017 Marzo	38	27	65
2017 Febrero	42	11	53
2017 Enero	36	6	42
2016 Diciembre	56	11	67
2016 Noviembre	79	15	94
2016 Octubre	102	20	122
2016 Septiembre	127	8	135
2016 Agosto	132	1	133
2016 Julio	194	7	201
2016 Junio	121	0	121
2016 Mayo	162	0	162
2016 Abril	136	0	136
2016 Marzo	156	0	156
2016 Febrero	183	0	183
2016 Enero	54	0	54
2015 Diciembre	38	0	38
2015 Noviembre	74	0	74

Mostrar todo

Indexada en:

Síguenos:

Estadísticas

Indexada en:

Síguenos:

Estadísticas

Suscríbase a la newsletter